As of November 6, 2026, Haemonetics Corp. is a publicly traded company (NYSE: HAE); its largest reported holder is Vanguard, with 5.59% on Schedule 13G of April 29, 2026, then Vanguard (5.26%). The largest insider holding is Christopher Simon, the chief executive and president, with 444,704 shares (0.98% of shares outstanding), per Form 4 of May 19, 2026 (Schedule 13G, April 29, 2026).
Is this your company?
About to sign with, pay or invest in Haemonetics Corp.? See the free Snapshot first.
Free to see. No signup.
Is Haemonetics Corp. a real, registered company?
- Haemonetics Corp files with the SEC under CIK 313143 (its SEC filings).
- Its shares are listed under the ticker HAE on NYSE (SEC company record).
- Incorporated in Massachusetts; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under HAEMONETICS CORP in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Martin Madaus, Director (Form 8-K filed 2026-07-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-04-30).
Who are Haemonetics Corp.'s owners and officers?
Haemonetics Corp.: incorporated in Massachusetts; business address in Boston, Massachusetts; industry Surgical & Medical Instruments & Apparatus (Schedule 13G/A, 2026-08-12).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-12 | Aqr Capital Management, LLC | 4.99% |
| Schedule 13G/A, 2026-05-13 | North Peak Capital Management, LLC | 0% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.26% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.59% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-03 | North Peak Capital Management, LLC | 5.1% |
| Schedule 13G, 2026-02-13 | Aqr Capital Management, LLC | 6.76% |
| Schedule 13G/A, 2025-08-12 | Wellington Management Group LLP | 4.6% |
Questions about who owns Haemonetics Corp.
Who owns Haemonetics Corp.?
On this page, 2 holders' latest ownership filings report 5% or more of Haemonetics Corp.: Vanguard Portfolio Management (5.59%, Schedule 13G, filed 2026-04-29) and Vanguard Capital Management (5.26%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Haemonetics Corp.?
By the share each holder's latest filing reports, the largest holders of Haemonetics Corp. on this page are Vanguard Portfolio Management (5.59%) and Vanguard Capital Management (5.26%).
When did Vanguard Portfolio Management buy into Haemonetics Corp.?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Portfolio Management on this page is the Schedule 13G, filed 2026-04-29, reporting 5.59%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Haemonetics Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Haemonetics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Haemonetics Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-28 | Martin Madaus | Director | appointed | |
| Form 8-K, 2026-05-01 | Charles J. Dockendorff | departed |
Which insiders own Haemonetics Corp. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 444,704 shares (0.98% of shares outstanding) (Form 4, 2026-05-19).
- , the general counsel and executive vice president: 68,829 shares (0.15% of shares outstanding) (Form 4, 2026-05-19).
- , the chief financial officer and executive vice president: 54,444 shares (0.12% of shares outstanding) (Form 4, 2026-05-19).
- , the senior vice president and human resources: 40,987 shares (0.09% of shares outstanding) (Form 4, 2026-06-08).
- , the executive vice president and chief commercial officer: 39,805 shares (0.09% of shares outstanding) (Form 4, 2026-11-03).
Shares outstanding: 45,537,511 as of 2026-10-30, from the company's latest SEC cover page.
How much has Haemonetics Corp. raised?
No fundraising or offering filing from Haemonetics Corp. is on file with us.
Keep reading
More on Haemonetics Corp. and the records around it.
Haemonetics Corp. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- North Peak Capital Management, LLC also filed stake reports on 2 other companies: GMR Solutions Inc. (Aug 2026), agilon health, inc. (Nov 2025)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/haemonetics